The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.
Jennifer Ann Woyach
Consultant or Advisory Role - Pharmacyclics (U)
Amy S. Ruppert
No relevant relationships to disclose
Gerard Lozanski
No relevant relationships to disclose
Arletta Lozanski
No relevant relationships to disclose
Nyla A. Heerema
Research Funding - Pharmacyclics
Weiqiang Zhao
No relevant relationships to disclose
Lynne Abruzzo
No relevant relationships to disclose
Amber Gordon
No relevant relationships to disclose
Jeffrey Alan Jones
Consultant or Advisory Role - Janssen; Pharmacyclics
Research Funding - Pharmacyclics
Joseph M. Flynn
No relevant relationships to disclose
Samantha Mary Jaglowski
Research Funding - Pharmacyclics
Leslie A. Andritsos
No relevant relationships to disclose
Farrukh Awan
No relevant relationships to disclose
Kristie A. Blum
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose
Amy J. Johnson
No relevant relationships to disclose
John C. Byrd
Research Funding - Pharmacyclics
Kami J. Maddocks
Research Funding - Pharmacyclics